Aquablation Therapy is the first surgical robotics system to receive a MedTech Innovation Briefing (MIB) from the National Institute for Health Care Excellence
07 3월 2023 - 9:00PM
PROCEPT® BioRobotics Corporation today announced Aquablation
Therapy received a MedTech Innovation Briefing (MIB) from the
National Institute for Health Care Excellence (NICE), for benign
prostate hyperplasia (BPH) in the United Kingdom. NICE has
recognized Aquablation Therapy is as effective as
transurethral resection of the prostate (TURP) for the removal of
prostate tissue for men with BPH. A panel of clinical experts said
the technology is innovative compared to the standard of care and
offers additional benefits, such as increased ability to preserve
sexual function. The clinical experts associated with the review
stated that the technology has the potential to replace TURP and
will challenge holmium laser enucleation for larger prostates.
Aquablation therapy is the first and only robotic surgical
system to receive a MIB. MIBs are designed to support
decision-making by health care professionals about the adoption and
impact of new technology through detailed technical, clinical and
economic assessments. New technology is selected on the basis of
high demand on the topic, the potential for useful clinical
outcomes, and whether evidence is available.
Mr. Neil Barber, one of the Briefings’ Clinical Experts and a
PROCEPT BioRobotics consulting physician, stated, “We have been
treating men successfully with Aquablation therapy for over seven
years and believe it will soon become the standard of care for BPH.
Patients ultimately want their work, leisure, and sex lives back
without risking long-term catheterization or loss of sexual
function. AquaBeam’s real time image guidance allows surgeons to
see a patient’s anatomy through a multidimensional view, allowing
for a fully customized treatment plan. The robot executes the
treatment plan and guides the waterjet with speed and accuracy
leading to a more consistent, predictable, and safer patient
outcome. Moreover, it is much easier to train new urologists to
become proficient using Aquablation therapy, which bodes well for
the future.”
“The NICE MedTech Innovation Briefing further validates the
value we believe Aquablation Therapy brings to patients, doctors,
hospitals and healthcare systems around the world,” said Sham
Shiblaq, Executive Vice President, Chief Commercial Officer of
PROCEPT® BioRobotics. “The robust body of clinical evidence shows
Aquablation therapy offers improved safety and durability when
compared to transurethral resection of the prostate, which is the
current gold standard surgical treatment option.”
About PROCEPT BioRobotics CorporationPROCEPT
BioRobotics is a surgical robotics company focused on advancing
patient care by developing transformative solutions in urology.
PROCEPT BioRobotics develops, manufactures and sells the AquaBeam
Robotic System, an advanced, image-guided, surgical robotic system
for use in minimally invasive urologic surgery with an initial
focus on treating benign prostatic hyperplasia, or BPH. BPH is the
most common prostate disease and impacts approximately 40 million
men in the United States. PROCEPT BioRobotics designed Aquablation
therapy to deliver effective, safe and durable outcomes for males
suffering from lower urinary tract symptoms, or LUTS, due to BPH
that are independent of prostate size and shape or surgeon
experience. The Company has developed a significant and growing
body of clinical evidence, which includes nine clinical studies and
over 150 peer-reviewed publications, supporting the benefits and
clinical advantages of Aquablation therapy.
Forward Looking StatementsThis release contains
forward‐looking statements within the meaning of federal securities
laws, including with respect to the Company’s projected financial
performance for full year 2022, statements regarding the potential
utilities, values, benefits and advantages of Aquablation® therapy
performed using PROCEPT BioRobotics’ products, including AquaBeam®
Robotic System, which involve risks and uncertainties that could
cause the actual results to differ materially from the anticipated
results and expectations expressed in these forward-looking
statements. You are cautioned not to place undue reliance on these
forward-looking statements. Forward-looking statements are only
predictions based on our current expectations, estimates, and
assumptions, valid only as of the date they are made, and subject
to risks and uncertainties, some of which we are not currently
aware. Forward-looking statements may include statements regarding
financial guidance, market opportunity and penetration, the
Company’s possible or assumed future results of operations,
including descriptions of the Company’s revenues, gross margin,
profitability, operating expenses, installed base growth,
commercial momentum, overall business or the overall macroeconomic
environment, which may impact customer spending or the Company’s
costs. Forward‐looking statements should not be read as a guarantee
of future performance or results and may not necessarily be
accurate indications of the times at, or by, which such performance
or results will be achieved. These forward‐looking statements are
based on the Company’s current expectations and inherently involve
significant risks and uncertainties. Actual results and the timing
of events could differ materially from those anticipated in such
forward‐looking statements as a result of these risks and
uncertainties. These risks and uncertainties are described more
fully in the section titled “Risk Factors” in the Company’s filings
with the Securities and Exchange Commission (the “SEC”), including
the Company’s annual report on Form 10-K filed with the SEC on
February 28, 2023. PROCEPT BioRobotics does not undertake any
obligation to update forward‐looking statements and expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward‐looking statements contained
herein. These forward-looking statements should not be relied upon
as representing PROCEPT BioRobotics’ views as of any date
subsequent to the date of this press release.
Important Safety Information
All surgical treatments have inherent and associated side
effects. For a list of potential side effects
visit https://aquablation.com/safety-information/.
Investor Contact:Matt Bacso, CFAVP, Investor
Relations and Business
Operationsm.bacso@procept-biorobotics.com
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024